BCIQ Profiles

Company Profile ReportTarget Profile Report
0908 Replicate
BioCentury & Getty Images

Emerging Company Profile

Replicate: optimizing the promise of self-replicating RNA

Emerging Company Profile: ATP unveils Replicate Bioscience with $40M and goal of harness dosing, safety advantages of the RNA tech 

ATP unveils Replicate Bioscience with $40 million and a goal of harness the dosing and safety advantages of self-replicating RNA.

Sep 9, 2021 | 12:59 AM GMT

Replicate is launching with a stable of optimized virally derived vectors to harness the dosing and safety advantages of self-replicating RNA.

The start-up brings together several leaders in self-replicating RNA, also known as self-amplifying RNA, with a $40 million series A round from founding investor Apple Tree Partners. ATP’s

Read the full 1057 word article

How to gain access

Continue reading with a
two-week free trial.